Sputnik V has been approved in 69 countries with a total population exceeding 3.7 billion people
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), an investor in the Russian Sputnik V vaccine against coronavirus, announced the results of its joint work with Ministries of Health and regulators of the leading countries to collect and analyse real-world vaccination data on the first anniversary of the vaccine’s registration confirming its high safety and efficacy profile.
Real-world data obtained during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and the UAE demonstrate a lack of serious adverse events (such as CVTs or myocarditis). In several countries where multiple vaccines are used, the Russian vaccine has demonstrated one of the best safety and efficacy parameters.
Sputnik V has also pioneered the unique heterogeneous boosting (vaccine cocktail) approach based on the use of two different human adenoviral vectors for two injections in the course of vaccination to achieve stronger and more durable immunity. This has become the core of the partnership of Sputnik V with other producers and this approach is now being followed by other producers as they try their vaccine combinations.
Sputnik V has been approved in 69 countries with a total population exceeding 3.7 billion people – nearly half of the global population.
RDIF has concluded production partnerships with more than 20 companies in 14 countries, including the leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.